Search clinical trials for: Pramlintide Insulin

Total 2836 results

Xeris Pharmaceuticals

Completed

Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D

Diabetes Mellitus, Type 1 | Insulin-dependent Diabetes Mellitus

United States
Montefiore Medical Center
Amylin Pharmaceuticals, LLC.

Completed

Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
AstraZeneca
Juvenile Diabetes Research Foundation

Completed

Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
AstraZeneca

Completed

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
McGill University
Canadian Institutes of Health Research (CIHR)

Recruiting

Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1 | Type 1 Diabetes | Postprandial Hyperglycemia

Canada
McGill University
Juvenile Diabetes Research Foundation

Completed

Pramlintide and Fiasp Closed-Loop With a Simple Meal Announcement

Type 1 Diabetes Mellitus

Canada
University of Virginia

Terminated

Glucagon Counterregulation in Type 1 Diabetes

Type 1 Diabetes Mellitus

United States
McGill University Health Centre/Research Institute...
Juvenile Diabetes Research Foundation

Recruiting

A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes (FCL)

Diabetes Mellitus, Type 1 | type1diabetes

Canada
University of Colorado, Denver
Amylin Pharmaceuticals, LLC.

Completed

Pramlintide in Adolescents With Type 1 Diabetes

Type 1 Diabetes

United States
University of Maryland, Baltimore
Amylin Pharmaceuticals, LLC.

Withdrawn

Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM

Type 2 Diabetes
Indonesia University

Unknown

The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus

Diabetes Mellitus

Indonesia
Boston University
National Institute on Aging (NIA)

Recruiting

Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease (DTAD)

Alzheimer Disease | Mild Cognitive Impairment

United States
ikfe-CRO GmbH
IKFE Institute for Clinical Research and Development

Unknown

Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use

Insulin-requiring Type 2 Diabetes Mellitus

Germany
AstraZeneca
Takeda Pharmaceuticals North America, Inc.

Terminated

A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects

Obesity

United States
University of Virginia
The Paul Manning Foundation

Terminated

Pramlintide Combined With Model Predictive Control Algorithm (ALM002)

Type 1 Diabetes Mellitus

United States
Diabetes Care Center
Amylin Pharmaceuticals, LLC.

Completed

The Effect of Pramlintide on Meal Time Insulin Bolus

Type 1 Diabetes
AstraZeneca

Completed

A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
Sanofi

Completed

Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes (SPIRIT)

Type 2 Diabetes Mellitus

Ukraine
Geropharm

Completed

Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients

Diabetes Mellitus, Type 2

Russian Federation
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes (BOOST)

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Austria, Switzerland, United Kingdom, Germany, Ireland
Danish Headache Center

Completed

Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patients

Migraine Without Aura

Denmark
AstraZeneca

Completed

Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide

Diabetes Mellitus, Non-Insulin-Dependent

United States
AstraZeneca

Completed

An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
University Diabetes & Endocrine Consultants
Amylin Pharmaceuticals, LLC.

Completed

A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

IDDM

United States
AstraZeneca

Completed

A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Egypt
Novo Nordisk A/S

Completed

Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark
AstraZeneca

Completed

Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

China
Novo Nordisk A/S

Completed

Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark, Sweden, Norway
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

Diabetes Mellitus, Type 2 | Diabetes

United Arab Emirates, Malaysia, India, South Africa, Algeria, Lebanon
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes (PreFER)

Diabetes Mellitus, Type 2 | Diabetes

Austria, Germany, Switzerland
Novo Nordisk A/S

Completed

Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.

Diabetes Mellitus, Type 2 | Diabetes

Japan
AstraZeneca

Completed

A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Obesity

United States
Novo Nordisk A/S

Completed

Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

China
AstraZeneca

Completed

Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

Obesity

United States
Emory University
Sanofi; University of Miami

Completed

Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes

Hyperglycemia | Diabetes

United States
AstraZeneca

Completed

A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Obesity

United States
Novo Nordisk A/S

Completed

Observational Study of Patients Using NovoRapid® or Soluble Human Insulin for Treatment of Type 2 Diabetes (UPGRADE)

Diabetes Mellitus, Type 2 | Diabetes

Italy
Novo Nordisk A/S

Completed

Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany, Poland, Russian Federation, Spain, Sweden, Netherlands, Singapore, Malaysia, France, Croatia, Romania, United Kingdom, Hong Kong
Novo Nordisk A/S

Completed

Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication (A1chieve®)

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Algeria, Argentina, Bangladesh, China, Egypt, India, Indonesia, Iran, Islamic Republic of, Jordan, Korea, Republic of, Libyan Arab Jamahiriya, Malaysia, Mexico, Morocco, Pakistan, Philippines, Russian Federation and more
Novo Nordisk A/S

Completed

Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, Spain, Germany, Finland, France
CPEX Pharmaceuticals Inc.

Completed

Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus (CPEX-011)

Type 2 Diabetes

United States
AstraZeneca

Completed

Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

Comparison of Two Formulations of Biphasic Insulin Aspart 70

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.

Diabetes Mellitus, Type 2 | Diabetes

Turkey
Novo Nordisk A/S

Completed

Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy Volunteers

Healthy | Diabetes

Japan
Novo Nordisk A/S

Completed

Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany

3

Subscribe